Nonetheless, it stands to reason that the effect of mycolactone on BCMA may potentiate the anti-BCMA therapies that are currently emerging against MM, giving mycolactone an additional key role in MM treatment. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.